See more : Sinocelltech Group Limited (688520.SS) Income Statement Analysis – Financial Results
Complete financial analysis of PT Bundamedik Tbk (BMHS.JK) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of PT Bundamedik Tbk, a leading company in the Medical – Care Facilities industry within the Healthcare sector.
- Seibu Holdings Inc. (9024.T) Income Statement Analysis – Financial Results
- The Clorox Company (CLX) Income Statement Analysis – Financial Results
- TVS Motor Company Limited (TVSMOTOR.BO) Income Statement Analysis – Financial Results
- ACTEOS S.A. (EOS.PA) Income Statement Analysis – Financial Results
- Qomel Co. (9600.SR) Income Statement Analysis – Financial Results
PT Bundamedik Tbk (BMHS.JK)
About PT Bundamedik Tbk
PT Bundamedik Tbk provides health care services in Indonesia. As of December 31, 2021, the company operated 2 maternal and child hospitals, 3 general hospitals, 2 clinics, 10 IVF clinics, and 14 diagnostic laboratories. It also engages in the distribution of drugs, pharmaceuticals, and medical devices; and hotel, medical tourism, and management consulting businesses. The company was founded in 1973 and is headquartered in Jakarta Pusat, Indonesia. PT Bunda Medik is a subsidiary of PT Bunda Investama Indonesia.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 1,488.20B | 1,658.69B | 1,710.76B | 1,148.14B | 964.89B | 852.23B |
| Cost of Revenue | 813.59B | 894.14B | 887.24B | 654.99B | 507.77B | 454.39B |
| Gross Profit | 674.61B | 764.55B | 823.52B | 493.15B | 457.12B | 397.84B |
| Gross Profit Ratio | 45.33% | 46.09% | 48.14% | 42.95% | 47.38% | 46.68% |
| Research & Development | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 198.24B | 149.18B | 137.94B | 100.46B | 88.10B | 105.07B |
| Selling & Marketing | 264.93B | 39.11B | 25.44B | 10.36B | 7.74B | 8.90B |
| SG&A | 463.17B | 188.29B | 163.39B | 110.82B | 95.84B | 113.98B |
| Other Expenses | 0.00 | 358.64B | 265.44B | 214.71B | 264.01B | 206.15B |
| Operating Expenses | 463.17B | 546.93B | 428.83B | 325.54B | 359.85B | 320.13B |
| Cost & Expenses | 1,276.76B | 1,441.07B | 1,316.06B | 980.53B | 867.62B | 774.52B |
| Interest Income | 8.42B | 8.36B | 7.96B | 4.73B | 2.04B | 1.97B |
| Interest Expense | 57.76B | 37.97B | 16.09B | 43.63B | 56.15B | 52.35B |
| Depreciation & Amortization | 113.55B | 120.22B | 85.13B | 67.74B | 51.98B | 44.13B |
| EBITDA | 203.45B | 344.13B | 570.28B | 265.85B | 155.81B | 122.53B |
| EBITDA Ratio | 13.67% | 19.62% | 28.22% | 21.51% | 15.19% | 13.89% |
| Operating Income | 211.44B | 216.83B | 416.19B | 188.68B | 101.61B | 77.71B |
| Operating Income Ratio | 14.21% | 13.07% | 24.33% | 16.43% | 10.53% | 9.12% |
| Total Other Income/Expenses | -171.12B | -39.63B | -7.95B | -74.00B | -51.83B | -53.60B |
| Income Before Tax | 40.32B | 176.79B | 398.89B | 144.99B | 45.44B | 24.11B |
| Income Before Tax Ratio | 2.71% | 10.66% | 23.32% | 12.63% | 4.71% | 2.83% |
| Income Tax Expense | 24.09B | 47.86B | 83.53B | 26.53B | 14.12B | 12.07B |
| Net Income | 7.46B | 128.93B | 315.36B | 118.46B | 31.32B | 5.13B |
| Net Income Ratio | 0.50% | 7.77% | 18.43% | 10.32% | 3.25% | 0.60% |
| EPS | 0.87 | 14.99 | 36.66 | 13.87 | 3.67 | 0.60 |
| EPS Diluted | 0.87 | 14.99 | 36.66 | 13.87 | 3.67 | 0.60 |
| Weighted Avg Shares Out | 8.60B | 8.60B | 8.60B | 8.54B | 8.54B | 8.60B |
| Weighted Avg Shares Out (Dil) | 8.60B | 8.60B | 8.60B | 8.54B | 8.54B | 8.60B |
Source: https://incomestatements.info
Category: Stock Reports